AusCann Group Holdings Ltd

Equities

AC8

AU000000AC89

Pharmaceuticals

Delayed Australian S.E. 02:10:35 2022-08-31 am EDT 5-day change 1st Jan Change
0.04 AUD -4.76% Intraday chart for AusCann Group Holdings Ltd -.--% -.--%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
AusCann Group Seeks to Raise Up to AU$1 Million Via Share Purchase Plan MT
AusCann Group Holdings Ltd Announces Change of Company Address CI
AusCann Group Holdings Limited Announces Company Secretary Changes CI
Auscann Group Appoints Nonexecutive Chair MT
AusCann Group Holdings Ltd Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Auscann's Expanded Partnership with European Cannabis to Bring EU GMP Certified Medicinal Cannabis to Aus, NZ MT
AusCann Group Holdings Limited Announces Executive Changes CI
Auscann Group Settles Sale of Facility in Wangara, Western Australia MT
Auscann Group Selling Western Australian Premises for Nearly AU$7 Million MT
Layton Mills and Margaret Curtis agreed to acquire 52% stake in CannPal Animal Therapeutics Limited from AusCann Group Holdings Ltd for AUD1. CI
AusCann Group Holdings Ltd Reports Earnings Results for the Half Year Ended December 31, 2022 CI
AusCann Group Holdings Ltd Announces Resignation of Krista Bates as Non-Executive Director CI
AusCann Group Holdings Ltd Auditor Raises 'Going Concern' Doubt CI
AusCann Group CEO Resigns MT
AusCann Group Holdings Ltd Announces the Resignation of Layton Mills as Chief Executive Officer CI
Auscann Group Enters Secured Loan Facility with European Cannabis MT
AusCann Group Holdings Ltd Reports Earnings Results for the Full Year Ended June 30, 2022 CI
AusCann Group Holdings Ltd Appoints Chris Mews as Chief Financial Officer CI
AusCann Group Holdings Ltd Enters Secured Commercial Loan Facility with Eurocann CI
AusCann Group Holdings Limited Enters Binding Term Sheet with European Cannabis Corporation Ltd CI
Auscann Group CFO to Step Down in April MT
AusCann Group Holdings Ltd Announces Resignation of Charles Altshuler as Chief Financial Officer, Effective April 7, 2022 CI
AusCann Group Holdings Ltd Reports Earnings Results for the Half Year Ended December 31, 2021 CI
Australian Shares Rebound on Improving Business Confidence MT
AusCann Secures Formal Guidance from US FDA for Veterinary Pain Drug MT
Chart AusCann Group Holdings Ltd
More charts
AusCann Group Holdings Limited is an Australia-based company focused on the development and commercialization of cannabinoid-derived therapeutic products to address unmet needs for humans and animals within Australia and internationally. Its products include Neuvis, CPAT-01, DermaCann and MicroMax. CPAT-01 is a liquid, oral veterinary medicine containing standardized tetrahydrocannabinol (THC) and cannabinoids (CBD) whole plant extracts in a proprietary ratio to target pain and inflammation in dogs. DermaCann is a CBD-derived nutraceutical in development for healthy skin and immune function in dogs with dermatological conditions. The product is a liquid oral oil formulation containing CBD in a patented combination with other bioactive lipids designed to target inflammation and immune modulation pathways. MicroMAX is an encapsulation technology for use in the field of animal therapeutics. Its subsidiaries include AusCann Operations Pty Ltd and CannPal Animal Therapeutics Limited.
More about the company
  1. Stock
  2. Equities
  3. Stock AusCann Group Holdings Ltd - Australian S.E.
  4. News AusCann Group Holdings Ltd
  5. AusCann : Completes Dose Tolerance Study, Files Registrations for Veterinary Product